Elixxer's pharmaceutical medical cannabis partner, Little Green Pharma of Australia, has successfully exported their first shipment of medicinal cannabis products for patients into the UK.
The products are to be distributed in the UK by Astral Health, a UK-based specialist importer and distributor of medicinal cannabis products and subsidiary of the Lyphe Group. The products were imported under the purchase agreement between the company and Astral Health previously announced to the ASX on 19 February 2020.
On 2 March 2020, the UK Home Office and MHRA announced that import permits may now be granted based on anticipated prescription quantities. This announcement sees improvements made to the access pathway for medicinal cannabis, increasing the efficiency of the process of exporting products to the UK.
LGP Managing Director Fleta Solomon said: “Little Green Pharma is one of a few companies with GMP-produced cannabinoid medicines available in the UK. We are proud to be leading the charge in helping patients across the globe access quality Australian medicinal cannabis products.”
Australia’s Minister for Health, the Honourable Greg Hunt said: “This first export of Australian-produced medicinal cannabis oils to the UK marks an important step in fulfilling Australia’s vision of building a global medicinal cannabis industry capable of supplying quality medicinal cannabis products to both Australian and overseas patients.”